151 related articles for article (PubMed ID: 18483358)
1. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.
De Bruyne E; Bos TJ; Asosingh K; Vande Broek I; Menu E; Van Valckenborgh E; Atadja P; Coiteux V; Leleu X; Thielemans K; Van Camp B; Vanderkerken K; Van Riet I
Clin Cancer Res; 2008 May; 14(10):2918-26. PubMed ID: 18483358
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines.
Drucker L; Tohami T; Tartakover-Matalon S; Zismanov V; Shapiro H; Radnay J; Lishner M
Carcinogenesis; 2006 Feb; 27(2):197-204. PubMed ID: 16113057
[TBL] [Abstract][Full Text] [Related]
3. Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.
De Bruyne E; Andersen TL; De Raeve H; Van Valckenborgh E; Caers J; Van Camp B; Delaissé JM; Van Riet I; Vanderkerken K
Leukemia; 2006 Oct; 20(10):1870-9. PubMed ID: 16900214
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibition results in decreased macrophage CD9 expression.
Wang XQ; Alfaro ML; Evans GF; Zuckerman SH
Biochem Biophys Res Commun; 2002 Jun; 294(3):660-6. PubMed ID: 12056820
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.
Wang JC; Bégin LR; Bérubé NG; Chevalier S; Aprikian AG; Gourdeau H; Chevrette M
Clin Cancer Res; 2007 Apr; 13(8):2354-61. PubMed ID: 17406028
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
[TBL] [Abstract][Full Text] [Related]
7. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival.
Vande Broek I; Leleu X; Schots R; Facon T; Vanderkerken K; Van Camp B; Van Riet I
Haematologica; 2006 Feb; 91(2):200-6. PubMed ID: 16461304
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of lentiviral transgene vectors in a large animal model.
Hofmann A; Kessler B; Ewerling S; Kabermann A; Brem G; Wolf E; Pfeifer A
Mol Ther; 2006 Jan; 13(1):59-66. PubMed ID: 16140581
[TBL] [Abstract][Full Text] [Related]
10. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia.
Yamazaki H; Xu CW; Naito M; Nishida H; Okamoto T; Ghani FI; Iwata S; Inukai T; Sugita K; Morimoto C
Biochem Biophys Res Commun; 2011 May; 409(1):14-21. PubMed ID: 21549094
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma.
Jost E; Gezer D; Wilop S; Suzuki H; Herman JG; Osieka R; Galm O
Cancer Lett; 2009 Aug; 281(1):24-31. PubMed ID: 19299079
[TBL] [Abstract][Full Text] [Related]
14. CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytolysis.
Shallal S; Kornbluth J
Blood; 2000 Jul; 96(1):224-33. PubMed ID: 10891455
[TBL] [Abstract][Full Text] [Related]
15. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.
López-Soto A; Folgueras AR; Seto E; Gonzalez S
Oncogene; 2009 Jun; 28(25):2370-82. PubMed ID: 19430493
[TBL] [Abstract][Full Text] [Related]
16. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.
Moreau P; Robillard N; Avet-Loiseau H; Pineau D; Morineau N; Milpied N; Harousseau JL; Bataille R
Haematologica; 2004 May; 89(5):547-51. PubMed ID: 15136217
[TBL] [Abstract][Full Text] [Related]
17. In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells.
Asosingh K; Günthert U; Bakkus MH; De Raeve H; Goes E; Van Riet I; Van Camp B; Vanderkerken K
Cancer Res; 2000 Jun; 60(11):3096-104. PubMed ID: 10850462
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of CD9 does not affect in vivo tumorigenic or metastatic properties of human prostate cancer cells.
Zvieriev V; Wang JC; Chevrette M
Biochem Biophys Res Commun; 2005 Nov; 337(2):498-504. PubMed ID: 16198313
[TBL] [Abstract][Full Text] [Related]
19. CD9 expression is not a prognostic factor in human osteosarcoma.
Kubista B; Erovic BM; Klinger H; Sulzbacher I; Trieb K
Cancer Lett; 2004 Jun; 209(1):105-10. PubMed ID: 15145525
[TBL] [Abstract][Full Text] [Related]
20. Genetic abnormalities and patterns of antigenic expression in multiple myeloma.
Mateo G; Castellanos M; Rasillo A; Gutiérrez NC; Montalbán MA; Martín ML; Hernández JM; López-Berges MC; Montejano L; Bladé J; Mateos MV; Sureda A; de la Rubia J; Díaz-Mediavilla J; Pandiella A; Lahuerta JJ; Orfao A; San Miguel JF
Clin Cancer Res; 2005 May; 11(10):3661-7. PubMed ID: 15897562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
